HZB 1043
Alternative Names: HZB-1043Latest Information Update: 18 Jul 2022
At a glance
- Originator Heilongjiang Zhenbaodao Pharmaceutical
- Class Antivirals
- Mechanism of Action Neuraminidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Influenza virus infections
Most Recent Events
- 18 Jul 2022 Preclinical trials in Influenza virus infections in China (Inhalation) before July 2022 (Heilongjiang Zhenbaodao Pharmaceutical, July 2022)